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ttp://dx.doi.org/10.1016/j.jmoldx.2016.03.004Chromosomal abnormalities are important for the risk stratiﬁcation of acute lymphoblastic leukemia/
lymphoma (ALL). However, approximately 30% of pediatric and 50% of adult patients lack abnormalities
with clinical relevance by traditional cytogenetic analysis. We integrated cytogenetic, ﬂuorescence in situ
hybridization, and whole-genome single-nucleotide polymorphism array results from 60 consecutive
clinical ALL cases. By cytogenetic and/or ﬂuorescence in situ hybridization analyses, recurring abnor-
malities with clinical relevance were observed in 33 B-cell ALL (B-ALL), including t(9;22), hyperdiploidy,
KMT2A translocation, ETV6-RUNX1, intrachromosomal ampliﬁcation of chromosome 21, near haploidy or
low hypodiploidy, and t(8;22). Single-nucleotide polymorphism array analysis found additional aberra-
tions with prognostic or therapeutic implication in 21 B-ALL and two T-cell ALL, including IKZF1 deletion,
intrachromosomal ampliﬁcation of chromosome 21 (one case with a normal karyotype), low hypodiploidy
(two cases with a normal karyotype), and one case each with fusion genes ETV6-NTRK3, CRLF2-P2RY8,
NUP214-ABL1, and SET-NUP214. IKZF1 deletion was noted in nine B-ALL with t(9;22), one B-ALL with
t(4;11), ﬁve B-ALL with a normal karyotype, and three B-ALL with nonrecurring karyotypic abnormalities.
Combining single-nucleotide polymorphism array with chromosome and ﬂuorescence in situ hybridization
assays, the detection rate for clinically signiﬁcant abnormal results increased from 56% to 75%. Whole-
genome single-nucleotide polymorphism array analysis detects cytogenetically undetectable
clinically signiﬁcant aberrations and should be routinely applied at diagnosis of ALL. (J Mol Diagn 2016,
18: 595e603; http://dx.doi.org/10.1016/j.jmoldx.2016.03.004)Supported by the Department of Pathology, University of Michigan, Ann
Arbor, MI.
Disclosures: None declared.Identiﬁcation of recurring cytogenetic abnormalities has had
a major effect on risk classiﬁcation of acute lymphoblastic
leukemia/lymphoma (ALL).1e4 Current therapeutic pro-
tocols consider a number of these abnormalities when
assigning patients to the high- or low-risk categories. For
example, hyperdiploidy (>50 chromosomes) and ETV6-
RUNX1 fusion gene confer the most favorable prognosis,
whereas near haploidy, low hypodiploidy or near triploidy,
t(9;22), and KMT2A (MLL) translocation are associated with
poor prognosis in B-cell ALL (B-ALL).1e3 In T-cell ALL
(T-ALL), t(11;14)(p13;q11), del(17p), and a complex kar-
yotype are associated with a poor overall survival.4
Karyotype and ﬂuorescence in situ hybridization (FISH)
analyses are the standard cytogenetic assays for identifying
genomic abnormalities. However, because of inadequatemerican Society for Investigative Pathology an
Y-NC-ND license (http://creativecommons.orgspecimens and absent or few mitotic cells, approximately
16% to 30% of the ALL cases yield no or inadequate
cytogenetic results. Among those with a cytogenetic result,
15% to 25% have a normal karyotype.2,5,6 Recent applica-
tion of whole-genome single-nucleotide polymorphism
(SNP) arrays, multiplex ligation-dependent probe ampliﬁca-
tion, and next-generation sequencing has revealed a plethora
of submicroscopic genomic abnormalities that speciﬁcally
target genes involved in key signaling pathways and are
associated with patient outcome.7e13 For example, submi-
croscopic deletions of genes CDKN2A/B, ETV6, IKZF1, andd the Association for Molecular Pathology.
/licenses/by-nc-nd/4.0).
Wang et alPAX5 have been frequently observed in B-ALL, and de-
letions of IKZF1, RB1, EBF1, and pseudoautosomal region 1
have been associated with an unfavorable prognosis.
High-resolution genome-wide SNP array analysis allows
determination of both copy number aberrations and copy
neutral loss of heterozygosity (CN-LOH) and therefore is
able to provide important insights into the often complex
and unique genomic proﬁles for many patients. SNP array
analysis requires only a small amount of DNA and can
provide useful information when specimens are limited or
metaphase cells are not available. In recent years, SNP
arrays have been used for detecting genomic abnormalities
in ALL and proved to facilitate diagnosis, risk stratiﬁcation,
and determination of efﬁcient therapeutic regimens.9e14
Despite these advantages, genome-wide SNP arrays have
not been routinely used for ALL by clinical laboratories.
This study retrospectively reviewed results of cytogenetics,
FISH, and whole-genome SNP array assays in 60 consec-
utive clinical ALL cases from a single institution. We found
that SNP array improved the detection rate of genomic
abnormalities (90% by cytogenetics and FISH versus 100%
by SNP array) and provided additional prognostic and
therapeutic information (56% by cytogenetics and FISH
versus 75% by cytogenetics, FISH, and SNP array). These
results indicate that whole-genome SNP arrays should be
incorporated as standard of care for ALL patients.
Materials and Methods
Patient Samples
Beginning in March 2014, we incorporated SNP array anal-
ysis as part of our standard clinical testing for patients with
newly diagnosed ALL. We retrospectively reviewed cytoge-
netic, FISH, and SNP array results for consecutive ALL cases
from the Clinical Cytogenetics Laboratory at the University of
MichiganHealth System betweenMarch 2014 and June 2015.
Sixty consecutive patients had SNP array results and 59 also
had concurrent cytogenetic and/or FISH analyses. Cytoge-
netic analysis was not performed in two patients with T-ALL;
FISH analysis was not performed in four patients with B-ALL
and two patients with T-ALL. This study was approved by the
institutional review board at the University of Michigan.
Cytogenetic and FISH Analyses
At least 20 G-banded metaphase cells were obtained from
overnight and/or 24-hour cultures using standard tech-
niques. Cases with <15 analyzable normal metaphase
cells were considered inadequate. FISH analysis was per-
formed using probe sets, including BCR-ABL1 dual fusion,
KMT2A breakapart, ETV6-RUNX1 fusion, and centromere
probes for chromosomes 4, 10, and 17 (Abbott Molecular,
Des Plaines, IL) for pediatric patients with B-ALL and
BCR-ABL1 and KMT2A probes for adults with B-ALL and
most patients with T-ALL. Some of the array results were596conﬁrmed by FISH analysis using probes commonly used in
the clinical cytogenetics laboratory. Karyotypic and FISH
results were interpreted according to the International System
for Human Cytogenetic Nomenclature. FISH images were
captured using a LeicaDMRAmicroscopewith the Cytovision
Imaging system (Leica Microsystems, Buffalo Grove, IL).SNP Array Analysis
Genomic DNA was extracted from leukemic blood, bone
marrow, or ﬂuidic samples using the QIAamp DNA mini-
extraction kit (Qiagen, Germantown, MD), according to the
manufacturer’s instructions. Genome-wide SNP array anal-
ysis was performed using the Affymetrix CytoScan HD
platform with approximately 2.7 million probes according to
the manufacturer’s protocols (Affymetrix, Santa Clara, CA)
as published previously.15
SNP array data were analyzed by the Affymetrix ChAS
software version 2.1 (Affymetrix). Plots of twoparameters, the
log2 ratio and the allele peaks, providing information
regarding copy number and genotype, respectively, were
examined by visual inspection. All genomic positions were
basedon the hg19 (2009) build of the humangenome sequence
(http://genome.ucsc.edu/cgi-bin/hgGateway, last accessed
March 17, 2016). Results were compared to databases of
known common copy number variations seen in healthy
controls, including the Toronto database of genomic variants
(http://dgv.tcag.ca/dgv/app/home, last accessed March 17,
2016), International Standards for Cytogenomic Arrays data-
base (http://dbsearch.clinicalgenome.org, last accessed
March 17, 2016), and Children’s Hospital of Philadelphia
copy number variation database (http://cnv.chop.edu, last
accessed March 17, 2016); common population variants were
excluded from the results. Gains or losses>35markers within
or including a known clinically signiﬁcant cancer-related gene
or >1 Mb outside the known clinical oncology signiﬁcant
regions and loss of heterozygosity >10 Mb are reported.Results
A total of 60 consecutive ALL cases were received between
March 2014 and June 2015 in the Clinical Cytogenetics
Laboratory for clinical SNP array analysis. Among those, 27
(45%) were from pediatric patients (0.5 to 18 years old), 13
(21.7%) were from young adults (19 to 30 years old), and 20
(33.3%) were from adults (31 to 70 years old). Fifty-three
patients (88.3%) were diagnosed as having B-ALL and
seven (11.7%) as having T-ALL.
Karyotypic abnormalities were found in 47 of 58 pa-
tients (81%), and FISH abnormalities were found in 42 of
54 patients (78%) (Table 1), among whom recurring
abnormalities with clinical relevance were observed in
33 patients with B-ALL. These abnormalities included
t(9;22)(q34;q11.2), hyperdiploidy, KMT2A translocation,
ETV6-RUNX1 fusion, intrachromosomal ampliﬁcation ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Comparison of Cytogenetic, FISH, and SNP Array Results
in 60 Consecutive Acute Lymphoblastic Leukemia/Lymphoma Cases
Results
No. of
samples (%)
Karyotype
Abnormal 47 (81)
t(9;22) 13
t(11q23)/KMT2A 4
Hyperdiploidy 8
Low hypodiploidy/near haploidy 2
t(8;22) 1
Normal 10 (17)
Inadequate 1 (2)
Total samples 58 (100)
FISH
Abnormal 42 (78)
BCR-ABL1* 13
KMT2A rearrangement 4
iAMP21 2
ETV6-RUNX1 4
ABL1 ampliﬁcation 1
Normal 12 (22)
Total samples 54 (100)
Abnormal karyotype and/or FISH 53 (90)
Recurring abnormality with prognostic
implication
33 (56)
Abnormal array 60 (100)
IKZF1 deletion 18
Hyperdiploidy 8
Low hypodiploidy/near triploidy 4
iAMP21y 3
ETV6-NTRK3 1
CRLF2-P2RY8z 1
NUP214-ABL1 ampliﬁcation 1
SET-NUP214 1
Combined cytogenetics, FISH and SNP array
results, recurring abnormality with clinical
relevance
45 (75)
*One case with BCR-ABL1 fusion also had ETV6-RUNX1 fusion.
yTwo of three cases with iAMP21 had IKZF1 deletion.
zThe case with CRLF2-P2RY8 fusion had IKZF1 deletion.
FISH, ﬂuorescence in situ hybridization; SNP, single-nucleotide
polymorphism.
SNP Array Improves ALL Prognosticationchromosome 21 (iAMP21), near haploidy or low hypodip-
loidy, and t(8;22)(q24.1;q11.2). An additional nine B-ALL
and four T-ALL cases had chromosome abnormalities with
unknown signiﬁcance. A normal karyotype was observed in
nine B-ALL and one T-ALL cases, among which six B-ALL
and the T-ALL cases had normal FISH results. One B-ALL
sample was inadequate for cytogenetic analysis, and ETV6-
RUNX1 fusion was observed by FISH analysis. No cytoge-
netic results were obtained for two patients with T-ALL, and
one of them was conﬁrmed to have ABL1 ampliﬁcation by
FISH analysis after SNP array analysis.
Abnormal array results were observed in all 60 ALL
cases. Clinically relevant aberrations with prognostic or
therapeutic implication were found in 34 cases. TheyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgincluded submicroscopic deletions that involved the IKZF1
gene, hyperdiploidy, low hypodiploidy or duplication of low
hypodiploidy, iAMP21, and the cryptic fusion genes CRLF2-
P2RY8, ETV6-NTRK3, NUP214-ABL1, and SET-NUP214.
Combining SNP array results with those from chromosome
and FISH assays, the detection rate for clinically relevant
results increased from 56% (33/59) to 75% (45/60).
Deletion of IKZF1 Gene in B-ALL
Submicroscopic deletion of the IKZF1 genewas detected in 18
B-ALL cases (30%) (Figure 1 and Supplemental Table S1).
The deletion sizes varied from 0.03 to 6.2 Mb, and most had
a proximal breakpoint within intron 3 (11/18, 61%). In
addition, deletion of exons 1 to 8 or the entire gene was
observed in three cases, and deletion of exons 2 to 6, 3 to 8,
1 to 6, 2 to 6/7, exon 1, and intron 3 was observed in one
case each. Case 18 had two deletions for the IKZF1 gene: a
proximal deletion of exon 1 and a distal deletion of exons
4 to 8. Case 11 had homozygous deletion of exons 2 to 6,
cases 10 and 12 had deletions of different sizes on homol-
ogous chromosomes, and the remaining 15 cases had
heterozygous deletions of IKZF1.
Among the cases with an IKZF1 deletion, ﬁve had a
normal karyotype (cases 1 to 5), two had iAMP21 (cases 5
to 6), two had nonrecurring chromosomal abnormalities
(cases 7 to 8), one had the t(4;11)(q21;q23) (KMT2A-AF4)
(case 9), and nine had the t(9;22) (BCR-ABL1) (cases 10 to
18) (Supplemental Table S1). In the ﬁve cases with a normal
karyotype, an IKZF1 deletion alone (case 4) or with other
submicroscopic SNP array aberrations was observed in each
case. Case 8 had a concomitant interstitial deletion of 316
kb at pseudoautosomal region 1, which results in juxtapo-
sition of the gene CRLF2 to exon 1 of P2RY8, forming a
fusion gene CRLF2-P2RY8. Patients with an IKZF1 deletion
in the absence of BCR-ABL1 are often referred for whole
exome sequencing to potentially identify targetable tyrosine
kinase mutations or fusions. For example, case 7 had a
novel fusion gene, JAK2-PPP1R12A, which is consistent
with the nonrecurring translocation t(9;12)(p24;q21) found
by karyotype analysis of this patient.
Low Hypodiploidy with 31 to 39 Chromosomes or Near
Triploidy
Low hypodiploidy with 31 to 39 chromosomes or near
triploidy due to duplication of low hypodiploidy was
detected in four B-ALL cases (6.7%) by SNP array (cases
26 to 29) (Supplemental Table S1). Cases 26 and 27 had a
normal karyotype, whereas cases 28 and 29 had abnormal
karyotypes. The SNP array revealed that case 26 had gain of
chromosomes 1, 5, 6, 8 to 11, 14, 18 to 22, X, and Y and
CN-LOH for chromosomes 3, 4, 7, 12, 13, and 15 to 17. The
gains were conﬁrmed by FISH analysis using the BCR-
ABL1 and ETV6-RUNX1 probes. This genomic proﬁle is
consistent with duplication of a low-hypodiploid clone with 38597
Exons 4-8, case 15 
E1 E2 E3 E4 E5 E6 E7 E8 
Exons 1-8, case 6 
Intron 3, case 16 
Exons 4-6/7, cases 1, 8, 14 
Exons 4-8, cases 2, 3 
Exons 3-8, case 4 
Entire gene, case 5 
Exons 4-6, cases 7, 9, 13 
Exons 4-8 and 4-6 on 
homologous chromosomes, 
case 10 
Homozygous deletion of exons 2-6, case 11 
Exons 1-6, case 17 
Exons 1 and 4-8, case 18 
Entire gene and exons 2-
6/7 on homologous 
chromosomes, case 12 
5’ 3’ 
Figure 1 Schematic diagram of distribution and composition of IKZF1 deletions in this study. The IKZF1 gene is oriented from 50 (left) to 30 (right). Empty
boxes represent coding exons (E) and the line connecting exons represents introns. Solid lines above the gene indicate heterozygous deletions, and dashed
lines indicate regions with homozygous deletion observed in each patient.
Wang et alchromosomes. Case 27 had loss of chromosomes 2, 3, 7, 12 to
17, and 20, consistent with a low-hypodiploid clone with 36
chromosomes. The karyotype of case 28 was interpreted as
near-haploid because of loss of the Y chromosome and gain
of an additional X chromosome in a male patient. The kar-
yotype was reinterpreted after SNP array results that the gain
of the X chromosome was actually a derivative chromosome
14 that was caused by an unbalanced translocation between
3q24q29 and 14p. Therefore, case 28wasmore consistent with
low hypodiploidy with 34 chromosomes. Case 29 had con-
current low-hypodiploid and near-triploid clones by chromo-
some analysis. SNP array conﬁrmed the relative losses and
gains; however, it could not distinguish the low-hypodiploid
clone from the near-triploid clone.
iAMP21
iAMP21 was detected in three B-ALL cases (5%) (cases 5,
6, and 30) (Figure 2 and Supplemental Table S1). Cases
6 and 30 had complex karyotypes, whereas case 5 had a
normal karyotype. FISH analysis using the ETV6-RUNX1
probes conﬁrmed ampliﬁcation of RUNX1 in the interphase
cells of all three cases; however, the iAMP21 was conﬁrmed
by metaphase FISH analysis only in the two cases with a
complex karyotype. No abnormal metaphase cells were
observed for case 5; however, the genomic proﬁle of chro-
mosome 21 has very characteristic intrachromosomal ampli-
ﬁcation involving RUNX1 and deletion of chromosome 21598terminal sequences,16 consistent with iAMP21, which was
also conﬁrmed by extramural expert consultation. Cases 5
and 6 also had concurrent deletion of IKZF1 gene.
Recurring Fusion Genes Detected by SNP Array Analysis
Recurring fusion genes were observed in two B-ALL (cases 8
and 24) and ﬁve T-ALL cases (cases 54 to 58) (Supplemental
Table S1). Case 8 had multiple aberrations by SNP array,
including the IKZF1 deletion and an interstitial deletion at
pseudoautosomal region 1 which results in CRLF2-P2RY8
fusion as mentioned above. Case 24 had an additional signal
for ETV6 gene on chromosome 15 by FISH analysis using the
ETV6-RUNX1 probes at the time of diagnosis, and further
analysis using the ETV6 break-apart probes revealed that only
30ETV6 sequences were translocated to chromosome 15
(Figure 3A). SNP array analysis of a sample obtained at
relapse revealedmultiple aberrations, including a terminal gain
of 12 Mb at 12p with the proximal breakpoint within intron 5
of theETV6 gene and a terminal loss of 10Mb on chromosome
15 with the proximal breakpoint within the NTRK3 gene.
These results indicate a cryptic unbalanced translocation
der(15)t(12;15), which creates an ETV6-NTRK3 fusion.
Recurring fusiongeneswere observed inﬁveof the sevenT-
ALL cases by SNP array. Case 54 had a 317-kb ampliﬁcation
at 9q34 with breakpoints within the NUP214 and ABL1 genes
(Figure 3B). Ampliﬁcationwas conﬁrmed by interphase FISH
analysis using the BCR-ABL1 probes; ﬁve to nine copies ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 Single-nucleotide polymorphism (SNP) array and ﬂuorescence in situ hybridization (FISH) results in acute lymphoblastic leukemia/lymphoma with
iAMP21.A: Copy number (top line) and allele peak (bottom panel) aberrations by SNP array in three cases with iAMP21. All cases have complex copy number gains and
losses with a common ampliﬁcation region at 21q22. RUNX1 gene (blue arrow) is within the common ampliﬁed region. B: FISH results using RUNX1 (red) and ETV6
(green) probes. iAMP21 was conﬁrmed by metaphase FISH analysis (white arrows) in cases 30 and 6; seven to 10 copies of RUNX1 per cell were observed in case 5 by
interphase FISH. Original magniﬁcation, 1000.
SNP Array Improves ALL PrognosticationABL1 per cell were observed. The ampliﬁcation with these
characteristic breakpoints is consistentwith anNUP214-ABL1
fusion due to circularization and episomal ampliﬁcation.17
Case 55 had a deletion of the long arm of chromosome 7 by
chromosome analysis; the SNP array detected multiple losses,
including the 7q deletion and also an interstitial deletion of
2.57 Mb at 9q34. The deletion of 9q34 juxtaposes 50 SET to
30NUP214 and forms a fusion gene, SET-NUP214. Case 56
had a complex karyotype with a t(10;11)(p12;q14), consistent
with an MLLT10-PICALM fusion, and a subclone with
duplication of the t(10;11). The SNP array identiﬁed many
aberrations, including a gain of 10p12.31q26.3 with a break-
point within MLLT10 and a gain of 11q14.2q25 with a
breakpoint slightly distal to thePICALM gene, suggesting that
only the der(10)t(10;11) was duplicated in the subclone. CaseThe Journal of Molecular Diagnostics - jmd.amjpathol.org57 had a deletion of 6q as a sole cytogenetic abnormality, and
case 58 had a normal karyotype; SNP array detected an
interstitial deletion of 63 kb at 1p33 in both cases. The deletion
resulted in a loss of exons 7 to 17 of the gene STIL and se-
quences between STIL and TAL1, placing TAL1 next to 50
sequences of STIL and forming a STIL-TAL1 fusion. These
two cases also shared in common CN-LOH of 9p, homozy-
gous loss of CDKN2A, and CN-LOH of 10q by SNP array.
Hyperdiploidy with >50 Chromosomes
Eight pediatric patients (13%) had hyperdiploidy with
favorable gains by chromosome and FISH analyses (cases
32 to 39) (Supplemental Table S1). The SNP array results
revealed gains consistent with the karyotype in case 38 and599
Figure 3 Single-nucleotide polymorphism (SNP)
array and ﬂuorescence in situ hybridization (FISH)
conﬁrmation in acute lymphoblastic leukemia/
lymphoma with fusion genes NTRK3-ETV6 (case 24)
and ABL1-NUP214 (case 54). A: Patient with B-cell
ALL with NTRK3-ETV6 (case 24). SNP array reveals a
terminal gain at 12p with a breakpoint within
intron 5 of ETV6 and a terminal loss of 15q with a
breakpoint within NTRK3. Metaphase FISH using
ETV6 (green)eRUNX1 (red) probes with reverse
DAPI banding reveals additional ETV6 signal on
chromosome 15 (blue arrow). ETV6 break-apart
probes (50 green, 30 red) with DAPI banding
reveals that 30ETV6 was translocated to chromo-
some 15 (white arrow). B: Patient with T-cell
ALL with ABL1-NUP214 ampliﬁcation (case 54).
SNP array detects an interstitial ampliﬁcation at
9q34 with proximal breakpoint within ABL1 and
distal breakpoint within NUP214. Interphase
FISH analysis using the BCR (green)eABL1 (red)
probes conﬁrmed ﬁve to nine copies of ABL1
in each cell. Original magniﬁcation, 1000 (A
and B).
Wang et aladditional abnormalities in the remaining seven cases. These
additional abnormalities include deletion of 9p involving
CDKN2A (cases 32 and 37), deletion of 12p with partial
deletion of ETV6 (case 36), multiple losses in case 39, and
CN-LOH of chromosomes 16 (case 33), 19 and 20 (case
34), 5 and 18 (case 35), 2, 13, 16, 20, and 22 (case 37).
Chromosome or FISH Abnormalities Not Detected by
SNP Array Analysis
Fifteen cases had apparently balanced translocations by
karyotype and/or FISH that were present in >20% of the600metaphase or interphase cells. These translocations included
KMT2A translocations (N Z 4), t(9;22) (N Z 8), and one
case each for t(2;21)(p21;q22) [together with the t(9;22)],
t(8;22), t(9;12), and t(14;15)(q11.2;q15). Submicroscopic
deletions at the translocation breakpoints were only detected
in the cases with t(8;22) and t(14;15), whereas the remaining
13 cases had no aberrations found at the translocation
breakpoints. Four B-ALL with t(9;22) also had an additional
Philadelphia chromosome in 15% to 95% of the metaphase
cells by karyotype; however, the additional Philadelphia
chromosome was only conﬁrmed by BCR-ABL1 FISH
analysis and SNP array in two cases. Interestingly, these twojmd.amjpathol.org - The Journal of Molecular Diagnostics
SNP Array Improves ALL Prognosticationcases (cases 12 and 16) had dual fusion signals in all the
abnormal interphase cells, consistent with a balanced t(9;22)
and no extra Philadelphia chromosome and no copy number
change at 9q34 or 22q11.2 by SNP array analysis. These
results suggested that the additional small chromosomes
were most likely other abnormalities that appeared to look
like a Philadelphia chromosome.Discussion
Although many studies have been published using SNP arrays
in ALL risk classiﬁcation, this is the ﬁrst study, to our
knowledge, that integrates cytogenetic, FISH, and SNP array
results in the clinical management of patients with B-ALL and
T-ALL. According to literature review,1e3 approximately
30% of pediatric and 50% of adult patients lack abnormalities
with clinical relevance for prognosis by traditional cytogenetic
analysis. In this study, we found 56% of patients with ALL
with clinically relevant abnormalities by chromosome and/or
FISH analyses. By incorporating whole-genome SNP array
analysis, the detection rate for clinically relevant abnormalities
increased to 75%. This result agrees with the rate published in
a previous review in which approximately 75% of childhood
ALL cases harbor a recurring chromosomal alteration detect-
able by karyotyping, FISH, or molecular techniques.8
The IKZF1 gene on chromosome 7p12.2 encodes the zinc
ﬁnger protein IKAROS that promotes differentiation, in-
hibits proliferation, and controls migration-related proper-
ties of hematopoietic cells.18,19 IKZF1 deletions are most
common in BCR-ABL1epositive cases and have been seen
in >60% of them; they have also been found in B-ALL with
other primary cytogenetic abnormalities.20e23 In our study, 9
of 13 BCR-ABL1-positive cases (69.2%) had an IKZF1
deletion. In addition, IKZF1 deletion was identiﬁed in the
BCR-ABL1 negative cases with iAMP21, KMT2A trans-
location, or a normal karyotype. In contrast, none of the cases
with ETV6-RUNX1 or hyperdiploidy, which are associated
with a favorable prognosis, had an IKZF1 deletion.
Deletion of IKZF1 is associated with poor response to in-
duction therapy and poor overall prognosis in B-ALL.12,22e25
IKZF1 has heterogeneity in the size of deletion with loss of
exons 4 to 7 as themost common focal mutation.12,20,25 Recent
studies also found that rare deletions have similarly poor or
worse effect on clinical outcome as the deletion of exons 4 to 7
or the entire gene.26 In this study, deletions of exons 4 to 6 or 7
were detected by SNP array in 17 of 18 cases; deletions of
entire gene, exons 2 to 6, 3 to 8, 1 to 6, 2 to 6/7, exon 1, and
intron 3 were also observed. Patients with IKZF1 deletion
often have concurrent mutations in the RAS and JAK/STAT5
pathways. Mutations in ABL1, EPOR, JAK2, PDGFRB,
EBF1, FLT2, IL7R, and SH2B3 have been reported.27,28
Fusion genes with kinase activity have also been seen in
these patients, such as CSF2RA-CRLF2, OFD1-JAK2, and
ETV6-NTRK3.29,30 CRLF2-P2RY8 and JAK2-PPP1R12A
were observed in our patient cohort. When tyrosine kinaseThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfusions are identiﬁed, these patients are potential candidates
for targeted therapies, which may signiﬁcantly improve out-
comes for such higher-risk patients.
It is not uncommon to have inadequate or normal cyto-
genetic results in ALL,2,5,6 which limits the value of karyo-
typic analysis in prognostication of ALL. In this study, SNP
arrays identiﬁed chromosome aberrations in 10 cases with a
normal karyotype and two cases with no karyotypic results.
They included the cytogenetic entities low hypodiploidy and
iAMP21. Low hypodiploidy has a nonrandom pattern of lost
and retained chromosomes, with chromosomes 3 and 7 most
commonly lost and chromosome 21 most often retained. Low
hypodiploidy or near triploidy is often associated with TP53
mutation and very poor survival.31 For iAMP21, the standard
method of detection is FISH by using probes directed to
RUNX1 to determine the copy number of the most highly
ampliﬁed region in metaphase cells. Three or more extra
copies of RUNX1 on a single abnormal chromosome 21
(a total of ﬁve or more RUNX1 signals per interphase cell)
deﬁne iAMP21.32,33 SNP array reveals a unique pattern of
ampliﬁcation and deletion within chromosome 21.16 Patients
with iAMP21 have a poor outcome and high relapse rate
when treated with standard therapy; however, if treated in the
intensive treatment arm, there is no signiﬁcant difference
in the outcome between these with or without iAMP21.34
Therefore, accurate identiﬁcation of iAMP21 is critical for
the proper risk stratiﬁcation and treatment. In the absence of
cytogenetics and/or metaphase FISH results with a probe for
RUNX1, array analysis should be considered.
CN-LOH and submicroscopic copy number changes were
found to be common in the hyperdiploid cases by SNP array
in this study. Approximately 15% to 20% of children with
hyperdiploid ALL relapse; however, the molecular mecha-
nisms that contribute to relapse are largely unknown. Gene
mutations within the RAS pathway and epigenetic regula-
tors were prominent in samples obtained from patients with
recurring disease.35,36 Because CN-LOH is often associated
with homozygous mutations of oncogenes or tumor sup-
pressor genes, useful correlations might be found between
particular chromosomes with CN-LOH and recurrent dis-
ease. Long-term follow-up and additional studies could help
elucidate the relevance of these additional abnormalities to
the patients’ clinical outcomes.
In this study, the array results reveal the presence of
fusion genes not routinely tested in ALL but with clinical
implication for prognosis or therapy, such as NUP214-
ABL1, ETV6-NTRK3, SET-NUP214, and CRLF2-P2RY8.
The presence of these recurring fusion genes with tyrosine
kinase activity can guide therapy of ALL. For example,
NUP214-ABL1 and ETV6-NTRK3 fusion genes are sensitive
to tyrosine kinase inhibitor therapy.30,37 Similarly, the
presence of SET-NUP214 fusion is associated with resis-
tance to corticosteroid/chemotherapy in T-ALL. and these
patients often have a poor prognosis.38
Current National Comprehensive Cancer Network guide-
lines (2015) emphasize the importance of clinical testing for601
Wang et alIKZF1 deletion in patients with ALL for prognostication and
treatment.39 Although multiplex ligation-dependent probe
ampliﬁcation is used in European laboratories for speciﬁc
detection of IKZF1 deletion, the test is gene speciﬁc and will
not detect submicroscopic abnormalities of other genomic
regions. High-resolution SNP array can detect IKZF1
deletions and other cryptic copy number aberrations as well
as CN-LOH that are not detectable by chromosome analysis.
Therefore, the SNP array is optimal as a complementary
assay to the existing chromosome and FISH assays. In
summary, our study reveals that SNP array signiﬁcantly
augments risk stratiﬁcation and guides treatment for patients
with ALL by detecting additional abnormalities of clinical
relevance. We recommend that SNP array be routinely
applied at diagnosis of ALL.Supplemental Data
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